Briefly noted: C Ma et al. Inflamm Bowel Dis 2017; 23: 833-9. This retrospective study examined the response to ustekinumab in 104 patients with Crohn’s disease. All patients had achieved a steroid-free ustekinumab induction. 92.3% had failed anti-TNFα therapy.
- 71.8% maintained a response at 52 weeks
- 64.4% maintained an endoscopic or radiographic response